Clinical response following adjuvant temozolomide in a patient with primary cerebral lymphoma

Anticancer Research

Volumn 24, Issue 6, 2004, Pages 4121-4125

  Strik, Herwig M ^a   Spreer, Annette ^a   Nagel, Holger ^a   Jacob, Sonja ^a   Jung, Wolfram ^a   Kitze, Bernd ^a   Bähr, Mathias ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

CNS lymphoma; CSF; Temozolomide

Indexed keywords

CYTARABINE; METHOTREXATE; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE;

AGED; ARTICLE; BRAIN LYMPHOMA; BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; DRUG SAFETY; FEMALE; HEALTH STATUS; HUMAN; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN;

EID: 14944378154     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. van der Sanden GA, Scheuten LJ, van Dijck JA, van Andel JP, van der Maazen RW and Coebergh JW: Primary central nervous system lymphomas: incidence and survival in the Southern and Eastern Netherlands. Cancer 94: 1548-1556, 2002.
2. Mead GM, Bleehen NM, Gregor A, Bullimore J, Shirley D, Rampling RP, Trevor J, Glaser MG, Lantos P, Ironside JW, Moss TH, Brada M, Whaley JB and Stenning SP: A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer 89: 1359-1370, 2000.
3. O'Neill BP, O'Fallon JR, Earle JD, Colgan JP, Brown LD and Krigel RL: Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy? Int J Radiat Oncol Biol Phys 33: 663-673, 1995.
4. Lachance DH, Brizel DM, Gockerman JP, Halperin EC, Burger PC, Boyko OB, Brown MT and Schold SC Jr: Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy. Neurology 44: 1721-1727, 1994.
5. DeAngelis LM, Seiferheld W, Schold SC, Fisher B and Schultz CJ: Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 20: 4643-4648, 2002.
6. Ferreri AJ, Reni M, Pasini F, Calderoni A, Tirelli U, Pivnik A, Aondio GM, Ferrarese F, Gomez H, Ponzoni M, Borisch B, Berger F, Chassagne C, Iuzzolino P, Carbone A, Weis J, Pedrinis E, Motta T, Jouvet A, Barbui T, Cavalli F and Blay JY: A multicenter study of treatment of primary CNS lymphoma. Neurology 58: 1513-1520, 2002.
7. O'Brien P, Roos D, Pratt G, Liew K, Barton M, Poulsen M, Olver I and Trotter G: Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 18: 519-526, 2000.
8. Treon SP and Chabner BA: Concepts in use of high-dose methotrexate therapy. Clin Chem 42: 1322-1329, 1996.
9. Abrey LE, DeAngelis LM and Yahalom J: Long-term survival in primary CNS lymphoma. J Clin Oncol 16: 859-863, 1998.
10. Herrlinger U, Schabet M, Brugger W, Kortmann RD, Kanz L, Bamberg M, Dichgans J and Weller M: Primary central nervous system lymphoma 1991-1997: outcome and late adverse effects after combined modality treatment. Cancer 91: 130-135, 2001.
11. Stupp R, Gander M, Leyvraz S and Newlands E: Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol 2: 552-560, 2001.
12. Reni M, Ferreri AJ, Landoni C and Villa E: Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. J Natl Cancer Inst 92: 575-576, 2000.
13. Herrlinger U, Kuker W, Platten M, Dichgans J and Weller M: First-line therapy with temozolomide induces regression of primary CNS lymphoma. Neurology 58: 1573-1574, 2002.
14. Lerro KA and Lacy J: Case report: a patient with primary CNS lymphoma treated with temozolomide to complete response. J Neurooncol 59: 165-168, 2002.
15. DeAngelis LM: Primary central nervous system lymphomas. Curr Treat Options Oncol 2: 309-318, 2001.
16. Hoang-Xuan K, Taillandier L, Chinot O, Soubeyran P, Bogdhan U, Hildebrand J, Frenay M, De Beule N, Delattre JY and Baron B: Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 21: 2726-2731, 2003.
17. Herrlinger U, Schabet M, Brugger W, Kortmann RD, Kuker W, Deckert M, Engel C, Schmeck-Lindenau HJ, Mergenthaler HG, Krauseneck P, Benohr C, Meisner C, Wiestler OD, Dichgans J, Kanz L, Bamberg M and Weller M: German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol 51: 247-252, 2002.